Novel Aroyl Pyrrole Derivatives as Antiproliferative Agents Against Breast and Colorectal Cancer Cells: Design, Synthesis and Biological Evaluation
Pharmaceuticals · 14.11.2026 · 19 (11) · 1805
DOI: 10.3390/ph19111805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 14.11.2026. Verfasst von Giuseppe Ruggieri und 15 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The development of resistance to conventional therapies remains one of the major challenges in the treatment of breast and colorectal cancers, highlighting the urgent need for novel anticancer agents with improved efficacy. In the present study, a series of novel aroyl pyrrole derivatives was designed and synthesized, evolving from the previously identified hit compound 1a, in order to investigate the influence of structural modifications on antitumor activity.
Methods
The antiproliferative activity of all compounds was evaluated in vitro against two human breast cancer cell lines (MCF7 and MDA-MB231) and two colorectal cancer cell lines (HT-29 and RKO).
Result
Among the synthesized derivatives, compound 3 emerged as the most active analog, displaying antiproliferative activity at low micromolar concentrations and significantly improved potency compared with the parent compound 1a in all tested cell lines. Furthermore, 3 did not show any significant cytotoxicity toward non-transformed HaCaT keratinocytes and normal dermal fibroblasts, suggesting a remarkable degree of selectivity for tumor cells. Flow cytometric analysis demonstrated that both 1a and 3 induced cell-cycle arrest at the G0/G1 phase in all four cancer cell lines, indicating inhibition of cell-cycle progression as one of the mechanisms underlying their antiproliferative activity. Furthermore, both compounds induce cell death in a small percentage of cells through a caspase-3/7-independent mechanism.
Conclusions
Overall, these findings identify 3 as a promising compound for the development of novel pyrrole-based anticancer agents and provide useful information on structure-activity relationships for the future optimization of this chemical scaffold.
Zitieren
APA
Ruggieri, G., Patacchini, E., Messore, A., Zarbo, L., Cara, E., Dente, U., Scipione, L., Saccoliti, F., Madia, V. N., Conte, L. D., Angiolini, V., Masuelli, L., Artico, M., Santo, R. D., Scarpa, S., & Costi, R. (2026). Novel Aroyl Pyrrole Derivatives as Antiproliferative Agents Against Breast and Colorectal Cancer Cells: Design, Synthesis and Biological Evaluation. Pharmaceuticals, 19(11), 1805. https://doi.org/10.3390/ph19111805
Vancouver
Ruggieri G, Patacchini E, Messore A, Zarbo L, Cara E, Dente U, et al. Novel Aroyl Pyrrole Derivatives as Antiproliferative Agents Against Breast and Colorectal Cancer Cells: Design, Synthesis and Biological Evaluation. Pharmaceuticals. 2026;19(11):1805. doi:10.3390/ph19111805
BibTeX
@article{Ruggieri2026,
author = {Ruggieri, Giuseppe and Patacchini, Elisa and Messore, Antonella and Zarbo, Laura and Cara, Emanuele and Dente, Utilio and Scipione, Luigi and Saccoliti, Francesco and Madia, Valentina Noemi and Conte, Letizia Del and Angiolini, Valentina and Masuelli, Laura and Artico, Marco and Santo, Roberto Di and Scarpa, Susanna and Costi, Roberta},
title = {Novel Aroyl Pyrrole Derivatives as Antiproliferative Agents Against Breast and Colorectal Cancer Cells: Design, Synthesis and Biological Evaluation},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1805},
doi = {10.3390/ph19111805}
}
EUVIMED